195 related articles for article (PubMed ID: 32111549)
1. Treatment outcomes of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw (MRONJ): A multicenter retrospective analysis in Japan.
Morishita K; Yamada SI; Kawakita A; Hashidume M; Tachibana A; Takeuchi N; Ohbayashi Y; Kanno T; Yoshiga D; Narai T; Sasaki N; Shinohara H; Uzawa N; Miyake M; Tominaga K; Kodani I; Umeda M; Kurita H
J Orthop Sci; 2020 Nov; 25(6):1079-1083. PubMed ID: 32111549
[TBL] [Abstract][Full Text] [Related]
2. A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration.
Ohbayashi Y; Iwasaki A; Nakai F; Mashiba T; Miyake M
Osteoporos Int; 2020 Mar; 31(3):577-585. PubMed ID: 31768589
[TBL] [Abstract][Full Text] [Related]
3. Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial.
Sim IW; Borromeo GL; Tsao C; Hardiman R; Hofman MS; Papatziamos Hjelle C; Siddique M; Cook GJR; Seymour JF; Ebeling PR
J Clin Oncol; 2020 Sep; 38(26):2971-2980. PubMed ID: 32614699
[TBL] [Abstract][Full Text] [Related]
4. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis.
Dos Santos Ferreira L; Abreu LG; Calderipe CB; Martins MD; Schuch LF; Vasconcelos ACU
Osteoporos Int; 2021 Dec; 32(12):2449-2459. PubMed ID: 34331067
[TBL] [Abstract][Full Text] [Related]
5. Teriparatide for the Treatment of Medication-Related Osteonecrosis of the Jaw.
Chopra K; Malhan N
Am J Ther; 2020 Jun; 28(4):e469-e477. PubMed ID: 32618592
[TBL] [Abstract][Full Text] [Related]
6. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
7. The role, efficacy and outcome measures for teriparatide use in the management of medication-related osteonecrosis of the jaw.
Anabtawi M; Tweedale H; Mahmood H
Int J Oral Maxillofac Surg; 2021 Apr; 50(4):501-510. PubMed ID: 32800674
[TBL] [Abstract][Full Text] [Related]
8. Effective ancillary role and long-term course of daily or weekly teriparatide treatment on refractory medication-related osteonecrosis of the jaw: a clinical case series.
Yoshiga D; Yoshioka I; Habu M; Sasaguri M; Tominaga K
Br J Oral Maxillofac Surg; 2022 Jun; 60(5):604-609. PubMed ID: 34996629
[TBL] [Abstract][Full Text] [Related]
9. Management of medication-related osteonecrosis of jaw: Comparison between icariin and teriparatide in a rat model.
Liu J; Mattheos N; Deng C; Su C; Wang Z; Luo N; Tang H
J Periodontol; 2021 Jan; 92(1):149-158. PubMed ID: 32281098
[TBL] [Abstract][Full Text] [Related]
10. Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings.
Kakehashi H; Ando T; Minamizato T; Nakatani Y; Kawasaki T; Ikeda H; Kuroshima S; Kawakami A; Asahina I
Int J Oral Maxillofac Surg; 2015 Dec; 44(12):1558-64. PubMed ID: 26304604
[TBL] [Abstract][Full Text] [Related]
11. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Osteonecrosis of the Jaw.
Yamachika E; Matsubara M; Ikeda A; Matsumura T; Moritani N; Iida S
J Craniofac Surg; 2015 Oct; 26(7):e575-7. PubMed ID: 26468825
[TBL] [Abstract][Full Text] [Related]
13. Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up.
Nisi M; Karapetsa D; Gennai S; Ramaglia L; Graziani F; Gabriele M
J Craniomaxillofac Surg; 2018 Jul; 46(7):1153-1158. PubMed ID: 29802059
[TBL] [Abstract][Full Text] [Related]
14. Short-Term Teriparatide and Recombinant Human Bone Morphogenetic Protein-2 for Regenerative Approach to Medication-Related Osteonecrosis of the Jaw: A Preliminary Study.
Jung J; Yoo HY; Kim GT; Lee JW; Lee YA; Kim DY; Kwon YD
J Bone Miner Res; 2017 Dec; 32(12):2445-2452. PubMed ID: 28815779
[TBL] [Abstract][Full Text] [Related]
15. Microarchitecture of medication-related osteonecrosis of the jaw (MRONJ); a retrospective micro-CT and morphometric analysis.
Schoenhof R; Munz A; Yuan A; ElAyouti A; Boesmueller H; Blumenstock G; Reinert S; Hoefert S
J Craniomaxillofac Surg; 2021 Jun; 49(6):508-517. PubMed ID: 33707134
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Medication-Related Osteonecrosis of the Jaw Around the Dental Implant With a Once-Weekly Teriparatide: A Case Report and Literature Review.
Kim JY; Park JH; Jung HD; Jung YS
J Oral Implantol; 2019 Oct; 45(5):403-407. PubMed ID: 31429640
[TBL] [Abstract][Full Text] [Related]
17. A Study of Oral Health Parameters and the Properties and Composition of Saliva in Oncological Patients with and without Medication-Related Osteonecrosis of the Jaw Who Take Bisphosphonates.
Sobczak-Jaskow H; Kochańska B; Drogoszewska B
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374277
[No Abstract] [Full Text] [Related]
18. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
19. Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors.
van Cann T; Loyson T; Verbiest A; Clement PM; Bechter O; Willems L; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Debruyne PR; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Support Care Cancer; 2018 Mar; 26(3):869-878. PubMed ID: 28963584
[TBL] [Abstract][Full Text] [Related]
20. Temporal correlation between bisphosphonate termination and symptom resolution in osteonecrosis of the jaw: a pooled case report analysis.
Hinson AM; Siegel ER; Stack BC
J Oral Maxillofac Surg; 2015 Jan; 73(1):53-62. PubMed ID: 25511956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
